The Top Line

Patent expirations push biopharma industry toward a tougher 2026

As AI evolves, the modern R&D lab is changing

The conversation centers on how advancements in AI and automation are prompting a re-evaluation of lab design in the biotech and pharmaceutical industries. Ryley Poblete from Gensler, highlights the shift from traditional, manual lab processes to automated systems that generate large datasets, necessitating a change in...

How physiology powers biotech innovation (Sponsored)

Autoimmune CAR-T: Navigating the FDA’s new regulatory playbook

Inside the sterile fill capacity crunch (Sponsored)

Trump's tariff threats, measured by manufacturing

Why patient access must keep pace with drug innovation (Sponsored)

What were the biggest clinical trial flops of 2025?

Community oncology’s growing role in the future of cancer care (Sponsored)

The biggest potential drug launches of 2026

How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)

Why human expertise still matters in AI-driven med comms (Sponsored)

Biopharma's rebound keeping pace so far

JPM26: Sunshine, AI and the deals that weren't

From approval to value: Why evidence storytelling now matters (Sponsored)

Drug approvals went from crawl to sprint in 2025

Putting patients first: from buzzword to business imperative (Sponsored)

Beyond the AI hype: How life sciences can turn agents into a competitive advantage (Sponsored)

China’s biotech moment goes global, Zai Lab exec says (Sponsored)

Biopharma CEOs assess the road ahead in 2026

The discussion centers on navigating the evolving biotech landscape, focusing on investment trends, manufacturing challenges, and direct-to-consumer models. The biotech investment market's recovery from a despondent start in 2025 is attributed to M&A activity and the return of generalist investors. Speakers emphasize t...